Genferon light suppositories 250000ME, No. 10

Vaginal or rectal suppositories

as a component of complex therapy - treatment of ARVI and other infectious diseases of bacterial and viral etiology in children;

for the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, incl. pregnant women, against the background of specific therapy prescribed and controlled by a doctor.

Vaginal or rectal suppositories: vaginal, rectal.

The route of administration, dosage and duration of the course depend on the age, the specific clinical situation. In adults and children over 7 years old, GenferonЃ Light is used at a dosage of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dosage of 125,000 IU of interferon alfa-2b per suppository. In women who are 13Ц40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository.

Recommended doses and treatment regimens

SARS and other acute viral diseases in children: 1 supp. rectally 2 times a day with a 12-hour interval in parallel with the main therapy for 5 days. If, after 5 days of treatment, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.

Chronic infectious and inflammatory diseases of viral etiology in children: 1 supp. rectally 2 times a day at 12-hour intervals along with standard therapy for 10 days. Then, within 1-3 months - 1 supp. rectally at night every other day.

Acute infectious and inflammatory diseases of the urogenital tract in children: 1 supp. rectally 2 times a day at 12-hour intervals for 10 days, against the background of specific therapy prescribed and controlled by a doctor.

Infectious and inflammatory diseases of the urogenital tract in pregnant women: 1 supp. (250,000 IU) vaginally 2 times a day at 12-hour intervals for 10 days, against the background of specific therapy prescribed and controlled by a doctor.

Infectious and inflammatory diseases of the urogenital tract in women: 1 supp. (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days, against the background of specific therapy prescribed and controlled by a doctor. With protracted forms, 3 times a week every other day, 1 supp. within 1-3 months.

Vaginal and rectal suppositories

1 supp.

interferon alpha-2b 250 thousand IU

taurine 5 mg

Vaginal or rectal suppositories

individual intolerance to interferon and other substances that make up the drug;

I trimester of pregnancy.

Pharmacodynamics

GENFERONЃ LIGHT is a combined preparation, the action of which is due to the components that make up its composition. It has a local and systemic effect.

The composition of GenferonЃ Light contains recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene has been genetically engineered.

Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by an increase in the cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8 + T-killers, NK-cells (natural killers), increased differentiation of B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the main histocompatibility complex type I,which increases the likelihood of recognition of infected cells by cells of the immune system. The activation of leukocytes contained in all layers of the mucous membrane under the influence of interferon ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by the reactions of the immune system, enhanced by the influence of interferon.

Taurine contributes to the normalization of metabolic processes and tissue regeneration, has a membrane stabilizing and immunomodulatory effect. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine contributes to the preservation of the biological activity of interferon, enhancing the therapeutic effect of the drug.

Pharmokinetics

With rectal administration of the drug, there is a high bioavailability (more than 80%) of interferon, and therefore both local and pronounced systemic immunomodulatory effects are achieved; with intravaginal use, due to the high concentration in the focus of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is reached 5 hours after the administration of the drug. The main route of elimination of? -Interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.

Side effect

The drug is well tolerated by patients. Local allergic reactions are possible (itching and burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after the termination of the administration. Continuation of treatment is possible after consulting a doctor.

To date, no serious or life-threatening side effects have been observed. There may be phenomena that occur with the use of all types of interferon alpha-2b, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leuko- and thrombocytopenia, but more often they occur when daily dose over 10,000,000 ME. In these cases, it is recommended to consult the attending physician to decide whether to discontinue the drug or reduce the dose.

As with any other preparation of interferon alpha, and in the case of an increase in temperature after its administration, a single dose of paracetamol at a dose of 500-1000 mg for adults and 250 mg for children is possible.

Drug interactions

GenferonЃ Light is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, a mutual potentiation of the action is observed, which makes it possible to achieve a high total therapeutic effect.